125 related articles for article (PubMed ID: 29046499)
1. The assessment of total antioxidant capacity and superoxide dismutase levels, and the possible role of manganese superoxide dismutase polymorphism in acromegaly.
Ilhan M; Turgut S; Turan S; Demirci Cekic S; Ergen HA; Korkmaz Dursun G; Mezani B; Karaman O; Yaylim I; Apak MR; Tasan E
Endocr J; 2018 Jan; 65(1):91-99. PubMed ID: 29046499
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of combined octreotide and cabergoline treatment in patients with acromegaly: a retrospective clinical study and review of the literature.
Suda K; Inoshita N; Iguchi G; Fukuoka H; Takahashi M; Nishizawa H; Yamamoto M; Yamada S; Takahashi Y
Endocr J; 2013; 60(4):507-15. PubMed ID: 23291436
[TBL] [Abstract][Full Text] [Related]
3. Association of the Ala16Val MnSOD gene polymorphism with plasma leptin levels and oxidative stress biomarkers in obese patients.
Becer E; Çırakoğlu A
Gene; 2015 Aug; 568(1):35-9. PubMed ID: 25958349
[TBL] [Abstract][Full Text] [Related]
4. Alterations in Concentration/Activity of Superoxide Dismutases in Context of Obesity and Selected Single Nucleotide Polymorphisms in Genes:
Lewandowski Ł; Kepinska M; Milnerowicz H
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32709094
[TBL] [Abstract][Full Text] [Related]
5. Decreasing mortality and changes in treatment patterns in patients with acromegaly from a nationwide study.
Esposito D; Ragnarsson O; Granfeldt D; Marlow T; Johannsson G; Olsson DS
Eur J Endocrinol; 2018 May; 178(5):459-469. PubMed ID: 29483205
[TBL] [Abstract][Full Text] [Related]
6. The efficacy of medical treatment in patients with acromegaly in clinical practice.
Lee SY; Kim JH; Lee JH; Kim YH; Cha HJ; Kim SW; Paek SH; Shin CS
Endocr J; 2018 Jan; 65(1):33-41. PubMed ID: 28931779
[TBL] [Abstract][Full Text] [Related]
7. The association of FOXO3A gene polymorphisms with serum FOXO3A levels and oxidative stress markers in vitiligo patients.
Ozel Turkcu U; Solak Tekin N; Gokdogan Edgunlu T; Karakas Celik S; Oner S
Gene; 2014 Feb; 536(1):129-34. PubMed ID: 24333267
[TBL] [Abstract][Full Text] [Related]
8. Acromegaly.
Scacchi M; Cavagnini F
Pituitary; 2006; 9(4):297-303. PubMed ID: 17077948
[TBL] [Abstract][Full Text] [Related]
9. Oxidative stress and reduced antioxidative status, along with endothelial dysfunction in acromegaly.
Anagnostis P; Efstathiadou ZA; Gougoura S; Polyzos SA; Karathanasi E; Dritsa P; Kita M; Koukoulis GN
Horm Metab Res; 2013 Apr; 45(4):314-8. PubMed ID: 23093460
[TBL] [Abstract][Full Text] [Related]
10. Systemic and pituitary pars intermedia antioxidant capacity associated with pars intermedia oxidative stress and dysfunction in horses.
McFarlane D; Cribb AE
Am J Vet Res; 2005 Dec; 66(12):2065-72. PubMed ID: 16379648
[TBL] [Abstract][Full Text] [Related]
11. Age- and Sex-Specific Differences as Predictors of Surgical Remission Among Patients With Acromegaly.
Park SH; Ku CR; Moon JH; Kim EH; Kim SH; Lee EJ
J Clin Endocrinol Metab; 2018 Mar; 103(3):909-916. PubMed ID: 29272449
[TBL] [Abstract][Full Text] [Related]
12. The Mexican Acromegaly Registry: Clinical and Biochemical Characteristics at Diagnosis and Therapeutic Outcomes.
Portocarrero-Ortiz LA; Vergara-Lopez A; Vidrio-Velazquez M; Uribe-Diaz AM; García-Dominguez A; Reza-Albarrán AA; Cuevas-Ramos D; Melgar V; Talavera J; Rivera-Hernandez AJ; Valencia-Méndez CV; Mercado M;
J Clin Endocrinol Metab; 2016 Nov; 101(11):3997-4004. PubMed ID: 27428551
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic trends and outcome of acromegaly: a single center experience over a 40-year period.
Karapanou O; Tzanela M; Christoforaki M; Papastathopoulou L; Moutsatsou P; Botoula E; Tsagarakis S
Hormones (Athens); 2016 Jul; 15(3):368-376. PubMed ID: 27394702
[TBL] [Abstract][Full Text] [Related]
14. Neuroendocrine tumors secreting growth hormone-releasing hormone: Pathophysiological and clinical aspects.
Gola M; Doga M; Bonadonna S; Mazziotti G; Vescovi PP; Giustina A
Pituitary; 2006; 9(3):221-9. PubMed ID: 17036195
[TBL] [Abstract][Full Text] [Related]
15. Antioxidant Capacity and Superoxide Dismutase Activity in Adrenoleukodystrophy.
Turk BR; Theisen BE; Nemeth CL; Marx JS; Shi X; Rosen M; Jones RO; Moser AB; Watkins PA; Raymond GV; Tiffany C; Fatemi A
JAMA Neurol; 2017 May; 74(5):519-524. PubMed ID: 28288261
[TBL] [Abstract][Full Text] [Related]
16. The association between treatment and systemic inflammation in acromegaly.
Wolters TLC; van der Heijden CDCC; Pinzariu O; Hijmans-Kersten BTP; Jacobs C; Kaffa C; Hoischen A; Netea MG; Smit JWA; Thijssen DHJ; Georgescu CE; Riksen NP; Netea-Maier RT
Growth Horm IGF Res; 2021; 57-58():101391. PubMed ID: 33964727
[TBL] [Abstract][Full Text] [Related]
17. Lifestyle predictors of oxidant and antioxidant enzyme activities and total antioxidant capacity in healthy women: a cross-sectional study.
Mahasneh AA; Zhang Y; Zhao H; Ambrosone CB; Hong CC
J Physiol Biochem; 2016 Dec; 72(4):745-762. PubMed ID: 27604761
[TBL] [Abstract][Full Text] [Related]
18. "Micromegaly": an update on the prevalence of acromegaly with apparently normal GH secretion in the modern era.
Butz LB; Sullivan SE; Chandler WF; Barkan AL
Pituitary; 2016 Dec; 19(6):547-551. PubMed ID: 27497970
[TBL] [Abstract][Full Text] [Related]
19. Patients lost to follow-up in acromegaly: results of the ACROSPECT study.
Delemer B; Chanson P; Foubert L; Borson-Chazot F; Chabre O; Tabarin A; Weryha G; Cortet-Rudelli C; Raingeard I; Reznik Y; Reines C; Bisot-Locard S; Castinetti F
Eur J Endocrinol; 2014 May; 170(5):791-7. PubMed ID: 24591552
[TBL] [Abstract][Full Text] [Related]
20. Progression of vertebral fractures despite long-term biochemical control of acromegaly: a prospective follow-up study.
Claessen KM; Kroon HM; Pereira AM; Appelman-Dijkstra NM; Verstegen MJ; Kloppenburg M; Hamdy NA; Biermasz NR
J Clin Endocrinol Metab; 2013 Dec; 98(12):4808-15. PubMed ID: 24081732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
